Jeffrey Siegel

10.7k total citations · 2 hit papers
41 papers, 6.1k citations indexed

About

Jeffrey Siegel is a scholar working on Immunology, Molecular Biology and Rheumatology. According to data from OpenAlex, Jeffrey Siegel has authored 41 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 11 papers in Molecular Biology and 9 papers in Rheumatology. Recurrent topics in Jeffrey Siegel's work include Immune Cell Function and Interaction (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Jeffrey Siegel is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Jeffrey Siegel collaborates with scholars based in United States, United Kingdom and Canada. Jeffrey Siegel's co-authors include M. Miles Braun, Sharon K. Gershon, William D. Schwieterman, Robert P. Wise, Joseph Keane, John Kasznica, Lawrence E. Samelson, Evelyne T. Edwards, Thomas R. Cupps and Niveditha Mohan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey Siegel

40 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 2.7k citations Joseph Keane, Sharon K. Gershon et al. New England Journal of Medicine profile →
Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 613 citations Niveditha Mohan, Evelyne T. Edwards et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Siegel United States	22	2.1k	1.8k	1.6k	1.5k	1.1k	41	6.1k
René R. P. de Vries Netherlands	51	3.3k 1.6×	1.0k 0.6×	972 0.6×	2.6k 1.8×	791 0.7×	138	7.3k
D Émilie France	38	2.2k 1.1×	950 0.5×	685 0.4×	1.0k 0.7×	690 0.6×	92	5.5k
Dominique Émilie France	43	3.5k 1.7×	1.4k 0.8×	451 0.3×	971 0.7×	729 0.6×	116	7.2k
Jason S. Knight United States	45	4.3k 2.1×	852 0.5×	1.7k 1.1×	1.9k 1.3×	464 0.4×	115	8.5k
Masayoshi Harigai Japan	46	1.9k 0.9×	1.3k 0.7×	487 0.3×	3.7k 2.5×	555 0.5×	345	8.1k
Frank Christiansen Australia	41	3.8k 1.9×	751 0.4×	596 0.4×	632 0.4×	411 0.4×	164	6.3k
Roberto Gerli Italy	52	2.7k 1.3×	628 0.3×	397 0.2×	3.0k 2.0×	1.1k 1.0×	267	8.0k
Lennart Truedsson Sweden	49	4.3k 2.1×	907 0.5×	367 0.2×	2.5k 1.7×	482 0.4×	186	7.6k
John Lister United States	39	1.1k 0.6×	824 0.5×	759 0.5×	415 0.3×	778 0.7×	178	7.2k
P. Sève France	44	1.0k 0.5×	611 0.3×	739 0.5×	1.1k 0.8×	845 0.7×	280	6.9k

Countries citing papers authored by Jeffrey Siegel

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Siegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Siegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Siegel more than expected).

Fields of papers citing papers by Jeffrey Siegel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Siegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Siegel. The network helps show where Jeffrey Siegel may publish in the future.

Co-authorship network of co-authors of Jeffrey Siegel

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Siegel. A scholar is included among the top collaborators of Jeffrey Siegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Siegel. Jeffrey Siegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khanna, Dinesh, Celia J. F. Lin, Daniel E. Furst, et al.. (2021). Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 205(6). 674–684. 72 indexed citations

Denton, Christopher P., Voon H Ong, Shiwen Xu, et al.. (2018). Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Annals of the Rheumatic Diseases. 77(9). 1362–1371. 125 indexed citations

Tesch, Greg H., Shashi Amur, John T. Schousboe, et al.. (2010). Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications. The AAPS Journal. 12(3). 243–253. 17 indexed citations

Costanzi, Stefano, Jeffrey Siegel, Irina G. Tikhonova, & Kenneth A. Jacobson. (2009). Rhodopsin and the Others: A Historical Perspective on Structural Studies of G Protein-Coupled Receptors. Current Pharmaceutical Design. 15(35). 3994–4002. 49 indexed citations

Felson, David T., Bin Zhang, & Jeffrey Siegel. (2008). Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable. Annals of the Rheumatic Diseases. 67(5). 580–583. 3 indexed citations

Baer, Alan N., et al.. (2006). Guillain‐Barré and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy. Arthritis & Rheumatism. 54(5). 1429–1434. 145 indexed citations

Block, Joel A., et al.. (2004). Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor. Clinical Infectious Diseases. 39(3). 295–299. 232 indexed citations

Mohan, Aparna, Timothy R. Coté, Jeffrey Siegel, & M. Miles Braun. (2003). Infectious complications of biologic treatments of rheumatoid arthritis. Current Opinion in Rheumatology. 15(3). 179–184. 50 indexed citations

Lee, Jong‐Hoon, Nancy R. Slifman, Sharon K. Gershon, et al.. (2002). Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis & Rheumatism. 46(10). 2565–2570. 337 indexed citations

10.

Mohan, Niveditha, Evelyne T. Edwards, Thomas R. Cupps, et al.. (2001). Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides. Arthritis & Rheumatism. 44(12). 2862–2869. 613 indexed citations breakdown →

11.

Keane, Joseph, Sharon K. Gershon, Robert P. Wise, et al.. (2001). Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent. New England Journal of Medicine. 345(15). 1098–1104. 2706 indexed citations breakdown →

12.

Blair, Patrick J., Lawrence Boise, Stephen P. Perfetto, et al.. (1997). Impaired Induction of the Apoptosis-Protective Protein Bcl-xL in Activated PBMC from Asymptomatic HIV-Infected Individuals. Journal of Clinical Immunology. 17(3). 234–246. 14 indexed citations

13.

Perfetto, Stephen P., Theresa E. Hickey, Patrick J. Blair, et al.. (1997). Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. Cytometry. 30(1). 1–9. 24 indexed citations

14.

Taylor, David & Jeffrey Siegel. (1995). Raf‐1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. European Journal of Immunology. 25(12). 3215–3221. 49 indexed citations

15.

Siegel, Jeffrey, Carl H. June, H Yamada, Ulf R. Rapp, & Lawrence E. Samelson. (1993). Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells.. The Journal of Immunology. 151(8). 4116–4127. 35 indexed citations

16.

Siegel, Jeffrey. (1992). Preparation and Analysis of Phosphorylated Proteins. Current Protocols in Immunology. 3(1). 11.2.1–11.2.17. 6 indexed citations

17.

June, C H, Mary C. Fletcher, J A Ledbetter, et al.. (1990). Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction.. Proceedings of the National Academy of Sciences. 87(19). 7722–7726. 456 indexed citations

18.

Siegel, Jeffrey, Richard D. Klausner, Ulf R. Rapp, & Lawrence E. Samelson. (1990). T cell antigen receptor engagement stimulates c-raf phosphorylation and induces c-raf-associated kinase activity via a protein kinase C-dependent pathway.. Journal of Biological Chemistry. 265(30). 18472–18480. 125 indexed citations

19.

Steinberg, A D, D M Klinman, Daniel L. Kastner, et al.. (1987). Genetic and molecular genetic studies of murine and human lupus.. PubMed. 14 Suppl 13. 166–76. 11 indexed citations

20.

Siegel, Jeffrey, Anthony L. Schwartz, Philip W. Askenase, & Richard K. Gershon. (1982). T-cell suppression and contrasuppression induced by histamine H2 and H1 receptor agonists, respectively.. Proceedings of the National Academy of Sciences. 79(16). 5052–5056. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact